Lilly Asia Ventures, a regional corporate venturing subsidiary of pharmaceutical firm Eli Lilly, reinvested in a round set to accelerate development of Abbisko's cancer-focused drug candidates.
China-based cancer immunotherapy producer Abbisko Therapeutics has closed a $123m series D round backed by Lilly Asia Ventures, a regional corporate venturing subsidiary of pharmaceutical firm Eli Lilly.
Investment firm Carlyle Group led the round, which included Temasek, Great Bay Area Homeland Development Fund, Warburg Pincus, OrbiMed, Lake Bleu Capital, Janchor Partners, Sage Partners, SHC, Qiming Venture Partners, Hankang Capital and CICC Capital.
Abbisko was founded in 2016 and is progressing seven cancer treatment candidates leveraging a mixture of small…
